PDF《长春达兴药业股份有限公司》

C

1 C * For identification purposes only The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

长春达兴药业股份有限公司CHANGCHUN DA XING PHARMACEUTICAL COMPANY LIMITED* (a joint stock limited company incorporated in the People's Republic of China) (Stock Code: 8067) ANNOUNCEMENT ? The Board is conducting Internal Enquiry on Irregularities it detected in its accounting records. PRC Police has made enquiry to the Company and Investigation is underway. ? Due to the Irregularities, there will be a delay in the publication of the Company's interim results for the six months ended

30 June 2005. At the request of the Company, trading in the shares of the Company on the Stock Exchange was suspended with effect from 10:00 a.m. on

28 July

2005 and will remain suspended until further notice. Irregularities in accounting records The directors ("Directors") of Changchun Da Xing Pharmaceutical Company Limited (the "Company") have detected certain irregularities in its accounting records (the "Irregularities"). The board of Directors (the "Board") is conducting enquiry on the Irregularities ("Internal Enquiry") and liaising with its bankers, customers and suppliers in clarifying its financial position. It is expected that the Internal Enquiry would take further time as majority of the existing executive directors of the Board are just appointed at the annual general meeting of the Company for the year ended

31 December

2004 held on

28 June 2005. As the Internal Enquiry is at its preliminary stage, the extent of the Irregularities is yet to be ascertained, the Company is not in a position to disclose further information on the Irregularities or to quantify the financial effects on the Company. The police department of the Government of the People's Republic of China ("PRC Police") has made enquiry to the Company and commenced investigation (the "Investigation") on the Irregularities which the Company is fully cooperating with. The Board will keep the public informed of any material developments on the Investigation if and when appropriate. C

2 C Delay in publication of interim results As the Internal Enquiry just commence, it is unlikely to get the Company's interim results for the six months ended

30 June

2005 ("Interim Results") released by

12 August

2005 as required by the Rules Governing the Listing of the Securities on The Growth Enterprise Market ("GEM Listing Rules") of The Stock Exchange of Hong Kong Limited (the "Stock Exchange"). For the time being, the Company cannot estimate when its Interim Results will be available for publication. The delay in the publication of the Interim Results constitutes breach of Rules 18.53 and 18.78 of the GEM Listing Rules. In this regard, the Stock Exchange reserves its right to take appropriate action against the Company. The Directors have not dealt in the shares of the Company since

12 July

2005 and will not do so until the publication of its Interim Results. At the request of the Company, trading in the shares of the Company on the Stock Exchange was suspended with effect from 10:00 a.m. on

28 July

2005 and will remain suspended until further notice. By order of the Board Changchun Da Xing Pharmaceutical Company Limited Qu Lian Qin Chairman Changchun, the PRC,